After receiving custom PCR reagents, a CLIA laboratory must decide whether the material is suitable for its own intended use and workflow. Supplier or development data can describe reagent design, production, and evaluation, but the laboratory remains responsible for establishing the performance specifications required for the test system it implements and for meeting its applicable quality and regulatory obligations.
Confirm the laboratory's intended use and complete workflow
Define analytes, specimen types, patient or use population, extraction, instruments, controls, result categories, interpretation, limitations, and reporting pathway. The reagent configuration is only one part of the test system. A change in specimen, extraction, instrument, reaction volume, or analysis can change the performance question.
Approve the method and performance plan
The laboratory director and qualified laboratory personnel should determine which characteristics are applicable and how they will be established. Under CLIA, performance specifications for non-FDA-cleared or approved systems and modified methods are established by the laboratory before reporting patient results. The exact study plan depends on the method and intended use.
Secure materials, comparators, and acceptance criteria
Plan representative samples or materials, comparator methods where appropriate, replicate structure, concentration ranges, relevant interferents, inclusivity or cross-reactivity questions, and invalid-result conditions. Acceptance criteria should be approved before data are reviewed so results are not judged retrospectively.
Verify the complete sample-to-result process
The laboratory should evaluate the workflow it will actually use, including collection or receipt, storage, extraction, reagent preparation, amplification, analysis, controls, interpretation, and reporting. Data from clean template alone does not establish performance in the final sample process.
Build quality procedures around the method
Document the procedure, control frequency and acceptance, calibration or instrument checks where applicable, maintenance, training, competency, corrective action, reagent storage, lot acceptance, result review, and record retention. Proficiency testing or an appropriate alternative assessment should be addressed according to applicable requirements.
Create a reagent-lot and change process
Agree how new lots will be identified, received, stored, assessed, and released for laboratory use. Define which supplier changes require communication and what the laboratory will review or re-evaluate. Establish reorder points and lead times so continuity does not depend on an emergency batch.
Keep supplier and laboratory roles explicit
A development or manufacturing partner can provide specifications, production records, certificates, evaluation data, technical information, and change notices within scope. The CLIA laboratory owns its intended use, establishment of performance specifications, validation or verification activities as applicable, quality system, implementation, and patient-result reporting.
Build the study plan from the final configuration
Performance work should reflect the reagent version, controls, extraction, instrument, software, analysis settings, specimen workflow, and operating procedures the laboratory intends to use. If a component or critical setting changes after the study, the laboratory needs a documented assessment of the effect. Beginning with a stable configuration reduces repeated work and creates a clearer link between evidence and the implemented test system.
Prepare an operational launch checklist
Before routine use, confirm approved procedures, staff training and competency processes, quality-control review, reagent receipt and storage, lot acceptance, equipment maintenance, result review, invalid-result handling, referral or escalation pathways, document control, and ongoing quality monitoring. Development support can make the reagent and technical package more usable, but these operational controls remain within the laboratory's own quality system and oversight.